• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

终末期肾病中的低钙血症、发病率和死亡率。

Hypocalcemia, morbidity, and mortality in end-stage renal disease.

作者信息

Foley R N, Parfrey P S, Harnett J D, Kent G M, Hu L, O'Dea R, Murray D C, Barre P E

机构信息

Division of Nephrology, Memorial University, St. John's, Nfld, Canada.

出版信息

Am J Nephrol. 1996;16(5):386-93. doi: 10.1159/000169030.

DOI:10.1159/000169030
PMID:8886175
Abstract

BACKGROUND

Hypocalcemia and hyperphosphatemia with secondary hyper-parathyroidism are characteristic of end-stage renal disease (ESRD). Although calcium levels critically affect almost all cellular processes, the impact of chronic hypocalcemia and other abnormalities of calcium-phosphate homeostasis on the prognosis of ESRD patients is unknown.

METHODS

An inception cohort of 433 patients starting ESRD therapy was followed prospectively for an average of 41 months. Serum calcium and other parameters were measured monthly. The mean calcium levels were 9.4 +/- 0.7 mg/dl. 23% of the patients had mean calcium levels < 8.8 mg/dl. After adjusting for baseline age, diabetes mellitus, ischemic heart disease, smoking and cholesterol levels, as well as serial albumin, hemoglobin, mean arterial blood pressure, phosphate and alkaline phosphatase levels, chronic hypocalcemia was strongly associated with mortality (RR 2.10, p = 0.006 for a mean calcium level < 8.8 mg/dl). The association with mortality was similar in hemodialysis (RR 2.10, p = 0.006) and peritoneal dialysis patients (2.67, p = 0.034). Using similar covariate adjustment, chronic hypocalcemia was associated with de novo ischemic heart disease (RR 5.23, p < 0.001), recurrent ischemic heart disease (RR 2.46, p = 0.006), de novo cardiac failure (RR 2.64, p < 0.001), and recurrent cardiac failure (RR 3.30, p < 0.001). Hypocalcemia retained its independent impact on morbidity and mortality when analyzed as a time-dependent covariate.

CONCLUSIONS

Chronic hypocalcemia, a very common, reversible feature of chronic uremia, is independently associated with morbidity and mortality in ESRD patients.

摘要

背景

低钙血症、高磷血症伴继发性甲状旁腺功能亢进是终末期肾病(ESRD)的特征。尽管钙水平对几乎所有细胞过程都有至关重要的影响,但慢性低钙血症及钙磷稳态的其他异常对ESRD患者预后的影响尚不清楚。

方法

对433例开始接受ESRD治疗的初治队列患者进行了平均41个月的前瞻性随访。每月测量血清钙及其他参数。平均钙水平为9.4±0.7mg/dl。23%的患者平均钙水平<8.8mg/dl。在对基线年龄、糖尿病、缺血性心脏病、吸烟和胆固醇水平,以及连续的白蛋白、血红蛋白、平均动脉血压、磷和碱性磷酸酶水平进行校正后,慢性低钙血症与死亡率密切相关(平均钙水平<8.8mg/dl时,相对危险度为2.10,p = 0.006)。血液透析患者(相对危险度为2.10,p = 0.006)和腹膜透析患者(相对危险度为2.67,p = 0.034)中,低钙血症与死亡率的关联相似。采用类似的协变量校正后,慢性低钙血症与新发缺血性心脏病(相对危险度为5.23,p<0.001)、复发性缺血性心脏病(相对危险度为2.46,p = 0.006)、新发心力衰竭(相对危险度为2.64,p<0.001)和复发性心力衰竭(相对危险度为3.30,p<0.001)相关。当作为时间依赖性协变量进行分析时,低钙血症对发病率和死亡率仍具有独立影响。

结论

慢性低钙血症是慢性尿毒症非常常见的可逆特征,与ESRD患者的发病率和死亡率独立相关。

相似文献

1
Hypocalcemia, morbidity, and mortality in end-stage renal disease.终末期肾病中的低钙血症、发病率和死亡率。
Am J Nephrol. 1996;16(5):386-93. doi: 10.1159/000169030.
2
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.慢性血液透析患者血清磷及钙磷乘积与死亡风险的关联:一项全国性研究
Am J Kidney Dis. 1998 Apr;31(4):607-17. doi: 10.1053/ajkd.1998.v31.pm9531176.
3
Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease.终末期肾病中的低白蛋白血症、心脏发病率和死亡率。
J Am Soc Nephrol. 1996 May;7(5):728-36. doi: 10.1681/ASN.V75728.
4
The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease.贫血对终末期肾病患者心肌病、发病率及死亡率的影响。
Am J Kidney Dis. 1996 Jul;28(1):53-61. doi: 10.1016/s0272-6386(96)90130-4.
5
Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease.高血压对终末期肾病患者心肌病、发病率及死亡率的影响
Kidney Int. 1996 May;49(5):1379-85. doi: 10.1038/ki.1996.194.
6
A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.帕立骨化醇治疗终末期肾病疗效与安全性的长期多中心研究
Clin Nephrol. 2001 Oct;56(4):315-23.
7
Association of Hypocalcemia With Mortality in Hospitalized Patients With Heart Failure and Chronic Kidney Disease.低钙血症与心力衰竭合并慢性肾脏病住院患者死亡率的相关性。
J Card Fail. 2015 Aug;21(8):621-7. doi: 10.1016/j.cardfail.2015.04.015. Epub 2015 May 14.
8
Prognostic significance of pre-end-stage renal disease serum alkaline phosphatase for post-end-stage renal disease mortality in late-stage chronic kidney disease patients transitioning to dialysis.在进入透析的晚期慢性肾脏病患者中,终末期肾病前血清碱性磷酸酶对终末期肾病后死亡率的预后意义。
Nephrol Dial Transplant. 2018 Feb 1;33(2):264-273. doi: 10.1093/ndt/gfw412.
9
Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.血清钙对血液透析患者甲状旁腺激素和碱性磷酸酶死亡率预测性的效应修饰作用:一项利用2005年至2012年台湾肾脏登记数据系统数据的调查
PLoS One. 2015 Jun 24;10(6):e0129737. doi: 10.1371/journal.pone.0129737. eCollection 2015.
10
Extended release nicotinic acid - a novel oral agent for phosphate control.缓释烟酸——一种用于控制磷酸盐的新型口服制剂。
Int Urol Nephrol. 2006;38(1):171-4. doi: 10.1007/s11255-006-0001-x.

引用本文的文献

1
Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumab.地诺单抗治疗后根据肾功能变化的血清磷酸盐、钙和甲状旁腺激素水平趋势
Osteoporos Int. 2025 Jul 12. doi: 10.1007/s00198-025-07601-2.
2
Mineral Bone Disease Prevalence and Biochemical Profile in Chronic Kidney Disease Patients Undergoing Hemodialysis.接受血液透析的慢性肾病患者的矿物质骨病患病率及生化特征
Cureus. 2025 May 24;17(5):e84747. doi: 10.7759/cureus.84747. eCollection 2025 May.
3
Course and treatment of severe osteoporosis complicated by calciphylaxis: a case report.
重度骨质疏松症合并钙化防御的病程及治疗:一例报告
JBMR Plus. 2024 Nov 22;9(1):ziae154. doi: 10.1093/jbmrpl/ziae154. eCollection 2025 Jan.
4
The different serum albumin assays influence calcium status in haemodialysis patients: a comparative study against free calcium as a reference method.不同血清白蛋白检测方法对血液透析患者钙状态的影响:以游离钙作为参考方法的对比研究
Clin Chem Lab Med. 2024 Dec 13;63(5):952-961. doi: 10.1515/cclm-2024-1030. Print 2025 Apr 28.
5
Personalizing electrolytes in the dialysis prescription: what, why and how?在透析处方中个性化定制电解质:是什么、为什么以及如何做?
Clin Kidney J. 2023 Oct 13;17(1):sfad210. doi: 10.1093/ckj/sfad210. eCollection 2024 Jan.
6
Serum phosphorus and calcium levels, and kidney disease progression in immunoglobulin A nephropathy.免疫球蛋白A肾病患者的血清磷、钙水平与肾脏疾病进展
Clin Kidney J. 2021 Jan 25;14(9):2108-2113. doi: 10.1093/ckj/sfab002. eCollection 2021 Sep.
7
Clinical Associations between Serial Electrocardiography Measurements and Sudden Cardiac Death in Patients with End-Stage Renal Disease Undergoing Hemodialysis.接受血液透析的终末期肾病患者连续心电图测量与心源性猝死之间的临床关联
J Clin Med. 2021 Apr 29;10(9):1933. doi: 10.3390/jcm10091933.
8
High prevalence of biochemical disturbances of chronic kidney disease - mineral and bone disorders (CKD-MBD) in a nation-wide peritoneal dialysis cohort: are guideline goals too hard to achieve?在全国性腹膜透析队列中,慢性肾脏病-矿物质和骨异常(CKD-MBD)的生化紊乱患病率很高:指南目标是否太难实现?
J Bras Nefrol. 2021 Apr-Jun;43(2):173-181. doi: 10.1590/2175-8239-JBN-2020-0147.
9
Glucagon-like peptide-1 receptor and sarcoglycan delta genetic variants can affect cardiovascular risk in chronic kidney disease patients under hemodialysis.胰高血糖素样肽-1受体和δ-肌聚糖基因变异可影响接受血液透析的慢性肾病患者的心血管风险。
Clin Kidney J. 2020 Feb 5;13(4):666-673. doi: 10.1093/ckj/sfz182. eCollection 2020 Aug.
10
Impact of Admission Calcium-phosphate Product on 1-year Mortality among Hospitalized Patients.入院时钙磷乘积对住院患者1年死亡率的影响。
Adv Biomed Res. 2020 Apr 22;9:14. doi: 10.4103/abr.abr_249_19. eCollection 2020.